Skip to main content

Table 1 Patient characteristics

From: Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma

  n. (%)
Total number of patients 100
Age  
   < 61 55 (55)
   ≥ 61 45 (45)
Clinical Stage  
   I, II 38 (38)
   III, IV 62 (62)
Performance status  
   0–1 77 (77)
   2–4 23 (23)
LDH  
   N≥ 52 (52)
   N < 48 (48)
Extranodal lesion  
   0–1 68 (68)
   2–4 32 (32)
IPI  
   Low/low-intermediate 58 (58)
   High/high-intermediate 42 (42)
Albumin  
   < 3.5 g/dl 26 (26)
   ≥3.5 g/dl 74 (74)
Prophylactic G-CSF  
   yes 62 (62)
   no 38 (38)
  1. N: normal range; IPI: international prognostic index; G-CSF: granulocyte colony-stimulating factor